Fibrocell launches anti-inflammatory pact with Intrexon; Halozyme inks $150M credit deal; Ohio biotech plots HQ move to San Diego

> Exton, PA-based Fibrocell Science ($FCSC) is teaming up with Intrexon ($XON) to develop genetically engineered fibroblasts to treat inflammatory conditions, with a special focus on arthritis. Fibrocell is handing over a $10 million tech access fee to get the partnership launched, with up to $52.5 million in development and commercial milestones for each new product that gets through to an approval. Fibrocell will also foot the bill for R&D. Release

> Halozyme Therapeutics ($HALO) inked a $150 million credit agreement after pledging royalties from its Enhanze products. Release

> The Ohio biotech Biosortia Pharmaceuticals is moving its HQ into J&J's ($JNJ) accelerator in San Diego after raising $500,000. Story

Suggested Articles

An FDA panel has narrowly backed the approval of Mallinckrodt’s terlipressin for a type of kidney failure that affects patients with cirrhosis.

A new biotech has come out of stealth with a funding round that includes “celebrity investors in artificial intelligence” as it aims to tackle aging.

GSK filed for patents on the lentiviral stable cell line technology before selling its rare disease gene therapy portfolio to Orchard in 2018.